Showing papers by "Cora N. Sternberg published in 2020"
TL;DR: Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supported care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy.
Abstract: Background Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by ch...
639 citations
Memorial Sloan Kettering Cancer Center1, University of Chicago2, Barwon Health3, Mayo Clinic4, Boston Children's Hospital5, Cork University Hospital6, University of Minnesota7, Copenhagen University Hospital8, Institut Gustave Roussy9, Fred Hutchinson Cancer Research Center10, Cornell University11, Sarah Cannon Research Institute12, Guy's Hospital13
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
Abstract: PURPOSEBRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We pres...
390 citations
University College London1, Oregon Health & Science University2, Harvard University3, Lund University4, Vita-Salute San Raffaele University5, University of Manchester6, University of British Columbia7, Monash University8, The Royal Marsden NHS Foundation Trust9, Columbia University10, University of Texas MD Anderson Cancer Center11, University of California, Davis12, University of Bologna13, University of California, San Francisco14, Institut Gustave Roussy15, Duke University16, Medical University of Vienna17, University of Cologne18, University of Oslo19, University of Washington20, Fred Hutchinson Cancer Research Center21, University of Melbourne22, Peter MacCallum Cancer Centre23, Northwestern University24, Cornell University25, Memorial Sloan Kettering Cancer Center26, American University of Beirut27, Tel Aviv University28, National and Kapodistrian University of Athens29, Tata Memorial Hospital30, Icahn School of Medicine at Mount Sinai31, Ghent University32, Belfast City Hospital33, Queen's University Belfast34, The Chinese University of Hong Kong35, University of California, Los Angeles36, University of Bern37, University of Minnesota38, Université de Montréal39, Tulane University40, Prostate Cancer Foundation41, University of Hamburg42, Toho University43, Université catholique de Louvain44, Radboud University Nijmegen45, University of St. Gallen46
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
255 citations
TL;DR: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgens-depRIvation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.
Abstract: Background Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapi...
211 citations
21 Apr 2020
TL;DR: CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
Abstract: PURPOSEIn prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly ch...
113 citations
TL;DR: Real-world insights on over 2500 patients with mCRPC supplement findings from randomized controlled trials and may help to inform clinical trial design, treatment guidelines, and clinical decision-making.
86 citations
St Bartholomew's Hospital1, Samsung Medical Center2, Macquarie University3, Karolinska University Hospital4, Université Paris-Saclay5, Princess Margaret Cancer Centre6, Yamagata University7, Cornell University8, Beth Israel Deaconess Medical Center9, Yale University10, Pfizer11, Fred Hutchinson Cancer Research Center12
TL;DR: Platinum-based chemotherapy is an active 1L regimen for advanced UC; however, progression-free survival and overall survival are generally short because of chemotherapy r...
Abstract: LBA1Background: Platinum-based chemotherapy is an active 1L regimen for advanced UC; however, progression-free survival (PFS) and overall survival (OS) are generally short because of chemotherapy r...
67 citations
Yale University1, Erasmus University Rotterdam2, University of British Columbia3, University of California, Los Angeles4, University of Tsukuba5, Complutense University of Madrid6, University of Sheffield7, National and Kapodistrian University of Athens8, University of Washington9, Akdeniz University10, National Cheng Kung University11, University of Tübingen12, University of Würzburg13, University of Ulsan14, University of Turin15, Rambam Health Care Campus16, University of Verona17, University of Barcelona18, Pompeu Fabra University19, Trakya University20, İnönü University21, Cornell University22, Wayne State University23, Eli Lilly and Company24, Queen Mary University of London25, University of Nebraska Medical Center26
TL;DR: Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma.
Abstract: Summary Background Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. Methods We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m2 (60 mg/m2 in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov , NCT02426125 ; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. Findings Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5–13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved with ramucirumab compared with placebo (4·1 months [95% CI 3·3–4·8] vs 2·8 months [2·6–2·9]; HR 0·696 [95% CI 0·573–0·845]; p=0·0002). Median overall survival was 9·4 months (95% CI 7·9–11·4) in the ramucirumab group versus 7·9 months (7·0–9·3) in the placebo group (stratified HR 0·887 [95% CI 0·724–1·086]; p=0·25). Grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients and with an incidence more than 2% higher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab group vs 16 [6%] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265). Serious adverse events were similar between groups (112 [43%] of 258 patients in the ramucirumab group vs 107 [40%] of 265 patients in the placebo group). Adverse events related to study treatment and leading to death occurred in eight (3%) patients in the ramucirumab group versus five (2%) patients in the placebo group. Interpretation Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma. Clinically meaningful benefit might be restricted in an unselected population. Funding Eli Lilly and Company.
60 citations
Hebron University1, University of California, San Diego2, Memorial Sloan Kettering Cancer Center3, University of California, San Francisco4, University of Michigan5, Harvard University6, Oregon Health & Science University7, Northwestern University8, National Institutes of Health9, University of Washington10, Icahn School of Medicine at Mount Sinai11, University of California, Los Angeles12, Cornell University13, Prostate Cancer Foundation14
TL;DR: How to accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms is discussed.
Abstract: Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms. Beltran and colleagues discuss the challenges in treating metastatic prostate cancer and strategies to accelerate precision oncology and improve therapy and clinical decisions in this setting.
41 citations
Paris Descartes University1, University of Düsseldorf2, Fred Hutchinson Cancer Research Center3, National and Kapodistrian University of Athens4, University of Utah5, Princess Margaret Cancer Centre6, NewYork–Presbyterian Hospital7, Memorial Sloan Kettering Cancer Center8, Icahn School of Medicine at Mount Sinai9, Vita-Salute San Raffaele University10
TL;DR: It is found that surgery of the primary tumor site is associated with improved survival in patients with metastatic UC who received standard chemotherapy, and this effect disappears in patients affected by two or more metastatic sites.
39 citations
Yale Cancer Center1, Beth Israel Deaconess Medical Center2, University of Milan3, Macquarie University4, University of Ulsan5, Netherlands Cancer Institute6, Rabin Medical Center7, Memorial Hospital of South Bend8, Bayer9, Bayer HealthCare Pharmaceuticals10, University of Tsukuba11, Cornell University12
TL;DR: Aberrant activation of fibroblast growth receptor (FGFR) signaling plays a role in UC and Rogaratinib, a pan-FGFR1-4 inhibitor, has promising efficacy and safety in pts with advanced mu...
Abstract: 489Background: Aberrant activation of fibroblast growth receptor (FGFR) signaling plays a role in UC. Rogaratinib, a pan-FGFR1-4 inhibitor, has promising efficacy and safety in pts with advanced mu...
TL;DR: This dissertation aims to provide a history of medical oncology and Hematology practice in Russia and its applications in the field of Prostate Cancer and Women's Health since the 1970s.
TL;DR: The quality-of-life outcomes from the CARD study, which significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor, are reported.
Abstract: Summary Background In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. Methods CARD was a randomised, multicentre, open-label, phase 4 study involving 62 clinical sites across 13 European countries. Patients (aged ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2) with confirmed metastatic castration-resistant prostate cancer were randomly assigned (1:1) by means of an interactive voice–web response system to receive cabazitaxel (25 mg/m 2 intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzalutamide (160 mg orally daily). Stratification factors were ECOG performance status, time to disease progression on the previous androgen signalling-targeted inhibitor, and timing of the previous androgen signalling-targeted inhibitor. The primary endpoint was radiographic progression-free survival; here, we present more detailed analyses of pain (assessed using item 3 on the Brief Pain Inventory-Short Form [BPI-SF]) and symptomatic skeletal events, alongside preplanned patient-reported outcomes, assessed using the Functional Assessment of Cancer Therapy—Prostate (FACT-P) questionnaire and the EuroQoL—5 dimensions, 5 level scale (EQ-5D-5L). Efficacy analyses were done in the intention-to-treat population. Pain response was analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of BPI-SF item 3, and patient-reported outcomes (PROs) were analysed in the intention-to-treat population with baseline and at least one post-baseline assessment of either FACT-P or EQ-5D-5L (PRO population). Analyses of skeletal-related events were also done in the intention-to-treat population. The CARD study is registered with ClinicalTrials.gov , NCT02485691 , and is no longer enrolling. Findings Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). Median follow-up was 9·2 months (IQR 5·6–13·1). Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p Interpretation Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor. Funding Sanofi.
TL;DR: The present review summarizes the results obtained treating advanced prostate cancer patients with immune-checkpoints inhibitors and analyzes potential mechanisms of both resistance and sensitivity, in order to hypothesize possible avenues of special interest for future research.
TL;DR: In this real-world setting, combination treatments with radium-223 and abiraterone/prednisone or enzalutamide were common and were more commonly given in a layered than a concurrent fashion.
Abstract: In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC). We used the Flatiron Health database to perform a retrospective study of patients with mCRPC treated with radium-223. Treatment with radium-223 plus abiraterone/prednisone or enzalutamide was defined as concurrent if both drugs started within 30 days of one another, or layered when the second drug started ≥30 days after the first. The index date was defined as the day of the first radium-223 dose. Outcome measures included symptomatic skeletal events (SSEs), overall survival (OS), and patterns of treatments received. Of the 625 patients treated with radium-223, 22% received it together with abiraterone/prednisone and 27% with enzalutamide. When these agents were combined, they were often initiated in a layered fashion (73% layered, 23% concurrent). Prior or concomitant bone health agents (BHAs) were received by 67% and 55% of patients, respectively. Median follow-up was 9 months. Overall, incidence rates for SSEs and pathologic fractures were 0.35 and 0.11 patients per person-year, respectively. Median OS from mCRPC diagnosis was 28.1 months. In this real-world setting, combination treatments with radium-223 and abiraterone/prednisone or enzalutamide were common. These agents were more commonly given in a layered than a concurrent fashion. Incidence rates for SSEs were reduced when BHAs were used; however, BHAs were underutilized.
TL;DR: Achievement in metastasis-free survival with PROSPER improves upon previous studies by at least 50% and up to 100% in women with previously undiagnosed breast cancer.
Abstract: 5515Background: PROSPER previously demonstrated a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) (hazard ratio [HR] 0.29; 95% CI 0.24-0.35; P < .0...
TL;DR: This data indicates that the prostate-specific membrane antigen (PSMA) can be targeted by antibodies (Ab) or small molecule ligands labeled with potent α emitters (e.g. 225Ac) but unlike ligands, Ab biodistribution...
Abstract: 114Background: Prostate-specific membrane antigen (PSMA) can be targeted by antibodies (Ab) or small molecule ligands labeled with potent α emitters (e.g. 225Ac). Unlike ligands, Ab biodistribution...
01 Jul 2020
TL;DR: In this paper, the authors performed an online survey among physicians involved in the treatment of metastatic clear cell renal cell carcinoma (mccRCC) patients and 41 experts responded to questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19.
Abstract: Background The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic. Methods We performed an online survey among physicians involved in the treatment of mccRCC, and 41 experts responded. Questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19. Findings For the majority of experts (73%), the combination of International metastatic renal cell carcinoma Database Consortium (IMDC) risk category and patient fitness are two important factors for decision-making. The main treatment choice in fit, favourable risk patients outside the pandemic is pembrolizumab/axitinib for 53%, avelumab/axitinib, sunitinib or pazopanib for 13% of experts each. During the pandemic, ICI-containing regimens are chosen less often in favour of a tyrosine kinase inhibitors (TKI) monotherapy, mainly sunitinib or pazopanib (35%). In fit, intermediate/poor-risk patients outside the pandemic, over 80% of experts choose ipilimumab/nivolumab, in contrast to only 41% of physicians during COVID-19, instead more TKI monotherapies are given. In patients responding to established therapies with ICI/ICI or ICI/TKI combinations, most participants modify treatment regimen by extending cycle length, holding one ICI or even both. Conclusion mccRCC treatment modifications in light of the coronavirus pandemic are variable, with a shift from ICI/ICI to ICI/TKI or TKI monotherapy.
TL;DR: It is shown that UC patients harbor a high prevalence of putative deleterious germline variants that truncate tumor suppressor proteins, suggesting a critical role for these pGVs in tumor progression.
Abstract: The prevalence and biological consequences of deleterious germline variants in urothelial cancer (UC) are not fully characterized. We performed whole-exome sequencing (WES) of germline DNA and 157 primary and metastatic tumors from 80 UC patients. We developed a computational framework for identifying putative deleterious germline variants (pDGVs) from WES data. Here, we show that UC patients harbor a high prevalence of pDGVs that truncate tumor suppressor proteins. Deepening somatic loss of heterozygosity in serial tumor samples is observed, suggesting a critical role for these pDGVs in tumor progression. Significant intra-patient heterogeneity in germline-somatic variant interactions results in divergent biological pathway alterations between primary and metastatic tumors. Our results characterize the spectrum of germline variants in UC and highlight their roles in shaping the natural history of the disease. These findings could have broad clinical implications for cancer patients.
TL;DR: In 35 atezolizumab-treated patients with pre-existing AID, incidences of special interest and treatment-related AEs appeared acceptable, and treating these patients requires caution, but pre- preexisting AID does not preclude atezoledzinumab therapy.
TL;DR: SG is an antibody-drug conjugate consisting of a humanized monoclonal anti–Trop-2 antibody coupled to the cytotoxic agent, SN-38, via a unique hydrolyzable linker.
Abstract: 5027Background: SG is an antibody-drug conjugate consisting of a humanized monoclonal anti–Trop-2 antibody coupled to the cytotoxic agent, SN-38, via a unique hydrolyzable linker. The epithelial ce...
TL;DR: PSA changes in the first 4wk of NGHT therapies are strongly associated with clinical outcome from mCRPC and can help guide early treatment switch decisions.
TL;DR: This secondary analysis of the PREVAIL and AFFIRM randomized clinical trials found that chemotherapy-naive men with new early bone lesions whose condition was stable or responding to enzalutamide had similar progression-free and overall survival times and a quality of life similar to that of men without new lesions whosecondition was responding to enzymes.
Abstract: Importance For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents healing, known as pseudoprogression, which can lead to premature discontinuation of therapy. Objective To determine the association between new unconfirmed lesions detected on a follow-up bone scintigram (bone scan) and outcomes in enzalutamide-treated men with mCRPC. Design, Setting, and Participants This post hoc, retrospective secondary analysis of 1672 enzalutamide-treated men from 2 phase 3, randomized mCRPC studies (PREVAIL and AFFIRM) before or after treatment with docetaxel was conducted from April 12, 2018, to July 25, 2019. Participants were men from the enzalutamide groups of the 2 studies with a decrease in prostate-specific antigen level at any time or with stable disease or soft-tissue disease responding to treatment based onradiologic findings. Intervention Enzalutamide, 160 mg once daily. Main Outcomes and Measures The clinical significance of new lesions detected on the first (early) or second (late) posttreatment bone scan, without an unfavorable change in prostate-specific antigen level or soft-tissue progression, was investigated. Associations of new unconfirmed lesions with radiographic progression-free survival, overall survival, decrease in prostate-specific antigen level, objective response in soft tissue, and quality of life were evaluated. Results Among the 643 men (median age, 72 years [range, 43-93 years]) in PREVAIL, early and late unconfirmed lesions were observed in 177 men (27.5%) with stable disease or disease responding to enzalutamide. Among the 404 men (median age, 70 years [range, 41-88 years]) in AFFIRM, early and late unconfirmed lesions were observed in 73 men (18.1%) with stable disease or disease responding to enzalutamide. In PREVAIL, men with new unconfirmed lesions had median radiographic progression-free survival (hazard ratio [HR], 1.37 [95% CI, 0.81-2.30];P = .23) and median overall survival (HR, 1.25 [95% CI, 0.85-1.83]) in the chemotherapy-naive setting similar to men those of men without such new lesions. In AFFIRM, the median overall survival (HR, 1.94 [95% CI, 1.10-3.44]) was reduced among men with unconfirmed bone lesions, but the median radiographic progression-free survival was not reduced (HR, 1.21 [95% CI, 0.83-1.75];P = .32). Quality of life over time was similar regardless of the presence of new unconfirmed lesions detected on a follow-up bone scan in either setting. Conclusions and Relevance These results suggest that new unconfirmed lesions detected on follow-up bone scans may represent pseudoprogression in men with mCRPC and are indicative of a favorable treatment response to enzalutamide. The detection of new unconfirmed bone lesions in men with mCRPC that responded to treatment with enzalutamide after docetaxel appears to be associated with worse overall survival and may represent true progression, thus highlighting the need for improved functional bone metastasis imaging. Trial Registration ClinicalTrials.gov Identifiers:NCT01212991andNCT00974311
Harvard University1, Fox Chase Cancer Center2, Fred Hutchinson Cancer Research Center3, University of Michigan4, University of Southampton5, Memorial Sloan Kettering Cancer Center6, Rabin Medical Center7, University Hospital of Lausanne8, Clatterbridge Cancer Centre NHS Foundation Trust9, University of North Carolina at Chapel Hill10, University of Utah11, City of Hope National Medical Center12, Icahn School of Medicine at Mount Sinai13
TL;DR: It is found that administering additional chemotherapy in patients who had significant residual disease despite preoperative chemotherapy is not frequent in clinical practice, and it did not clearly increase overall survival.
TL;DR: IPATential150 evaluated the potential associations between PTEN loss, placebo, and Ipat + Abi in patients with 1L mCRPC (NCT03072238) with the aim of establishing a causal relationship between these losses and disease progression.
Abstract: 182Background: IPATential150 is a randomized trial comparing Ipat + Abi vs placebo + Abi in patients (pts) with 1L mCRPC (NCT03072238). We evaluated the potential associations between PTEN loss, ge...
TL;DR: The standard-dose schedule for radium-223 high-dose or extended-schedule regimens remained one of the standard therapies for patients with symptomatic mCRPC and could not be implemented in a large proportion of patients due to disease progression.
TL;DR: This data indicates that certain sites of PSMA expression (e.g. salivary/lacrimal glands, kidneys, small bowel) are not affected by antibodies or small molecules targeting PSMA with different biodistribution.
Abstract: 5560Background: Antibodies (Abs) or small molecules can target PSMA with different biodistribution. Certain sites of PSMA expression (e.g. salivary/lacrimal glands, kidneys, small bowel) are not ac...
TL;DR: While PCWG2-defined PSA progression was associated with radiographic progression in enzalutamide-treated men, the findings argue for prospective re-evaluation of this threshold.